Display options
Cite
Ansari J, Ravipati HP, Munker R, et al. Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer. J Community Support Oncol. 2015;13(11):411-4doi: 10.12788/jcso.0189.
Ansari, J., Ravipati, H. P., Munker, R., Cotelingam, J. D., Shackelford, R. E., & Prouty, L. A. (2015). Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer. The Journal of community and supportive oncology, 13(11), 411-4. https://doi.org/10.12788/jcso.0189
Ansari, Junaid, et al. "Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer." The Journal of community and supportive oncology vol. 13,11 (2015): 411-4. doi: https://doi.org/10.12788/jcso.0189
Ansari J, Ravipati HP, Munker R, Cotelingam JD, Shackelford RE, Prouty LA. Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer. J Community Support Oncol. 2015 Nov;13(11):411-4. doi: 10.12788/jcso.0189. PMID: 26863022.
Copy Download .nbib Format: NLM
Share it on

J Community Support Oncol. 2015 Nov;13(11):411-4. doi: 10.12788/jcso.0189.

Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer.

The Journal of community and supportive oncology

Junaid Ansari, Hari P Ravipati, Reinhold Munker, James D Cotelingam, Rodney E Shackelford, Leonard A Prouty

Affiliations

  1. Feist Weiller Cancer Center, LSU Health, Shreveport, Louisiana, USA. [email protected].
  2. Feist Weiller Cancer Center, LSU Health, Shreveport, Louisiana, USA.
  3. Department of Pathology, LSU Health, Shreveport, Louisiana, USA.
  4. Departments of Pathology and Pediatrics, LSU Health, Shreveport, Louisiana, USA.

PMID: 26863022 DOI: 10.12788/jcso.0189

Abstract

Secondary leukemia is a common late complication after exposure to cancer therapies such as chemotherapy and radiotherapy. With the increase in the overall survival of cancer patients over the past 3 decades, treatment-related malignant neoplasms have increased in incidence. Secondary leukemias due to breast cancer and Hodgkin lymphoma have been studied in detail, but to our knowledge only a few case studies have reported secondary leukemias with previous lung cancer.¹⁻⁴ Lung cancer is the leading cause of cancer death in the United States.⁵ Since the overall survival (OS) as well as the progression-free survival (PFS) of lung cancer has improved, secondary malignancies, which are usually aggressive and have a poor prognosis, have become a common occurrence among survivors. The use of concurrent chemo-radiotherapy could increase the risk for secondary cancers. Here we report the case of a patient who developed treatment-related acute myelogenous leukemia (t-AML) with a likely prior myelodysplasia (t-MDS) after receiving combined chemo-radiotherapy for lung cancer.

©2015 Frontline Medical Communications.

Keywords: chemotherapy; lung cancer; radiotherapy; second malignancies; therapy-related AML; therapy-related MDS

Publication Types